Variability in response to antiplatelet therapy can be explained in part by
pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of …

Pharmacogenetic variants can alter the mechanism of action (pharmacodynamic gene
variants) or kinetic processes such as absorption, distribution, metabolism and elimination …

CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …

Antiplatelet therapy with clopidogrel is the current standard of care for coronary artery
disease patients undergoing a percutaneous coronary intervention. However, approximately …

The CYP2C19* 2 loss‐of‐function allele is associated with reduced generation of active
metabolites of clopidogrel. However, meta‐analyses have supported or discounted the …

CYP2C19 is one of the principal enzymes involved in the bioactivation of the antiplatelet
prodrug clopidogrel. A common loss‐of‐function allele, CYP2C19* 2 (c. 681G> A; …

Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

Clopidogrel has become the mainstay oral antiplatelet regimen to prevent recurrent
ischemic events after acute coronary syndromes or stent placement. However, there is …

The widespread use of clopidogrel alone or in combination with aspirin has significantly
benefited patients with acute coronary syndrome who are managed medically or by …

Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C,
polypeptide 19)* 2 and* 3 alleles leads to a loss of functional protein, and carriers of these …